Short answer
Celldex Therapeutics, Inc. (CLDX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Celldex announced third-quarter 2026 financial results on November 5, 2026.
Celldex Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Celldex announced third-quarter 2026 financial results on November 5, 2026
- Detailed financial figures and operating commentary are contained in Exhibit 99.1, the accompanying press release
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 EMBARQ-CSU1 and CSU2 met primary and key secondary endpoints, supporting barzolvolimab’s potential in chronic spontaneous urticaria
- BLA submission for barzolvolimab in CSU anticipated in 2027, creating a defined regulatory catalyst
- Cash, cash equivalents and marketable securities $650.3M, funding planned operations through 2028 per management
- Q3 R&D expense $67.4M, up from $62.9M, reflecting higher barzolvolimab trial and manufacturing costs
- Q3 net loss $75.6M, or $0.96 per share, versus $67.0M, or $1.01 per share, in 2025
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Celldex Therapeutics, Inc. 8-K filings
Get the next CLDX 8-K as it lands
Follow CLDX for push alerts, or ask the research agent what this filing means.